2021
Distinct roles of KLF4 in mesenchymal cell subtypes during lung fibrogenesis
Chandran RR, Xie Y, Gallardo-Vara E, Adams T, Garcia-Milian R, Kabir I, Sheikh AQ, Kaminski N, Martin KA, Herzog EL, Greif DM. Distinct roles of KLF4 in mesenchymal cell subtypes during lung fibrogenesis. Nature Communications 2021, 12: 7179. PMID: 34893592, PMCID: PMC8664937, DOI: 10.1038/s41467-021-27499-8.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsCell ProliferationDisease Models, AnimalDown-RegulationExtracellular MatrixFemaleFibroblastsFibrosisHumansKruppel-Like Factor 4LungLung InjuryMaleMesenchymal Stem CellsMiceMice, Inbred C57BLMyofibroblastsReceptor, Platelet-Derived Growth Factor betaRespiratory Tract DiseasesSignal TransductionTransforming Growth Factor betaConceptsMesenchymal cell typesPlatelet-derived growth factor receptorSmooth muscle actinLung fibrosisKruppel-like factor 4Forkhead box M1Growth factor receptorCell transitionCell typesExtracellular matrixDistinct rolesKLF4Box M1C chemokine ligandMesenchymal cell subtypesFactor receptorPro-fibrotic effectsFactor 4PDGFRMesenchymeCellsMacrophage accumulationKLF4 levelsChemokine ligandLung fibrogenesis
2020
Specialized Smooth Muscle Cell Progenitors in Pulmonary Hypertension
Saddouk F, Ntokou A, Greif D. Specialized Smooth Muscle Cell Progenitors in Pulmonary Hypertension. 2020, 25-30. DOI: 10.1007/978-981-15-1185-1_4.ChaptersSmooth muscle cellsPulmonary hypertensionNormal lungArteriole smooth muscle cellsPulmonary artery complianceSmooth muscle cell progenitorsStrong independent predictorPlatelet-derived growth factor receptorKruppel-like factor 4Diverse cardiovascular diseasesHypoxia-inducible factorGrowth factor receptorArtery complianceIndependent predictorsTherapeutic optionsIdiopathic formCardiovascular diseaseDependent signaling contributesSignaling contributesHypertensionSMC progenitorsMuscle cellsFactor receptorNon-cell autonomous mannerCell progenitors
2018
NCK-dependent pericyte migration promotes pathological neovascularization in ischemic retinopathy
Dubrac A, Künzel SE, Künzel SH, Li J, Chandran RR, Martin K, Greif DM, Adams RH, Eichmann A. NCK-dependent pericyte migration promotes pathological neovascularization in ischemic retinopathy. Nature Communications 2018, 9: 3463. PMID: 30150707, PMCID: PMC6110853, DOI: 10.1038/s41467-018-05926-7.Peer-Reviewed Original ResearchConceptsNeovascular tuftsPericyte migrationMural cellsPathological neovascular tuftsPDGF-B overexpressionTreatment of retinopathyOxygen-induced retinopathyCapillary barrier functionΑ-SMA expressionPlatelet-derived growth factor receptorPlatelet-derived growth factorPhosphorylation of PDGFRβGrowth factor receptorIschemic retinopathyProliferative retinopathyEndothelial-specific knockoutVascular leakagePericyte depletionPathological neovascularizationGenetic lineage tracingMouse modelPericyte proliferationNck2 adaptor proteinRetinopathyBarrier function
2015
Smooth muscle cell progenitors are primed to muscularize in pulmonary hypertension
Sheikh AQ, Misra A, Rosas IO, Adams RH, Greif DM. Smooth muscle cell progenitors are primed to muscularize in pulmonary hypertension. Science Translational Medicine 2015, 7: 308ra159. PMID: 26446956, PMCID: PMC4629985, DOI: 10.1126/scitranslmed.aaa9712.Peer-Reviewed Original ResearchConceptsSmooth muscle cellsKruppel-like factor 4Pulmonary hypertensionSmooth muscleHypoxia-induced pulmonary hypertensionPathogenesis of PHPulmonary artery blood pressureSMC progenitorsArteriole smooth muscleArtery blood pressureSmooth muscle cell progenitorsCardiovascular disease pathogenesisPlatelet-derived growth factor receptorHypoxia-induced expressionGrowth factor receptorPH patientsBlood pressurePulmonary arteriolesVascular disordersTherapeutic strategiesDisease pathogenesisKLF4 levelsKLF4 expressionDistal extensionMuscle cellsVascular Mural Cells Promote Noradrenergic Differentiation of Embryonic Sympathetic Neurons
Fortuna V, Pardanaud L, Brunet I, Ola R, Ristori E, Santoro MM, Nicoli S, Eichmann A. Vascular Mural Cells Promote Noradrenergic Differentiation of Embryonic Sympathetic Neurons. Cell Reports 2015, 11: 1786-1796. PMID: 26074079, DOI: 10.1016/j.celrep.2015.05.028.Peer-Reviewed Original ResearchConceptsPlatelet-derived growth factor receptorNA differentiationNoradrenergic differentiationMural cell recruitmentDorsal aortaSympathetic neuronsCloche mutantsCell recruitmentZebrafish embryosEmbryonic sympathetic neuronsGrowth factor receptorVascular mural cellsSmooth muscle targetsPostganglionic sympathetic neuronsSympathetic nervous systemMural cellsSympathetic precursorsFactor receptorVascular maturationDifferentiationMuscle toneMuscle targetsNeurovascular interactionsHeart rateNervous system
2014
Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma
Kaley TJ, Wen P, Schiff D, Ligon K, Haidar S, Karimi S, Lassman AB, Nolan CP, DeAngelis LM, Gavrilovic I, Norden A, Drappatz J, Lee EQ, Purow B, Plotkin SR, Batchelor T, Abrey LE, Omuro A. Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma. Neuro-Oncology 2014, 17: 116-121. PMID: 25100872, PMCID: PMC4483051, DOI: 10.1093/neuonc/nou148.Peer-Reviewed Original ResearchConceptsVascular endothelial growth factor receptorPhase II trialWorld Health OrganizationGrowth factor receptorII trialPrimary endpointOverall survivalExploratory cohortIntratumoral hemorrhageGrade 3Small molecule tyrosine kinase inhibitorsSingle-arm phase II trialMalignant meningioma patientsRadiographic response rateMedian overall survivalEffective medical therapyProgression-free survivalFactor receptorEndothelial growth factor receptorPlatelet-derived growth factor receptorTyrosine kinase inhibitorsExpression of VEGFR2MR perfusion imagingHigh-grade meningiomasMedian PFSCorrelation of Somatic Mutations and Clinical Outcome in Melanoma Patients Treated with Carboplatin, Paclitaxel, and Sorafenib
Wilson MA, Zhao F, Letrero R, D'Andrea K, Rimm DL, Kirkwood JM, Kluger HM, Lee SJ, Schuchter LM, Flaherty KT, Nathanson KL. Correlation of Somatic Mutations and Clinical Outcome in Melanoma Patients Treated with Carboplatin, Paclitaxel, and Sorafenib. Clinical Cancer Research 2014, 20: 3328-3337. PMID: 24714776, PMCID: PMC4058354, DOI: 10.1158/1078-0432.ccr-14-0093.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorCarboplatinDouble-Blind MethodFemaleFollow-Up StudiesGenotypeGTP PhosphohydrolasesHumansMaleMelanomaMembrane ProteinsMiddle AgedMutationNeoplasm StagingNiacinamidePaclitaxelPhenylurea CompoundsPrognosisProto-Oncogene Proteins B-rafSkin NeoplasmsSorafenibSurvival RateConceptsProgression-free survivalNRAS-mutant melanomaPlatelet-derived growth factor receptorPerformance statusClinical outcomesNRAS mutationsCox proportional hazards modelVEGF receptorsSomatic mutationsWorse performance statusGood performance statusImproved clinical responseKaplan-Meier methodClinical trial populationsPretreatment tumor samplesSite of diseaseProportional hazards modelEffect of sorafenibBRAF-mutant melanomaFisher's exact testGrowth factor receptorClinical responseOverall survivalClinicopathologic featuresMelanoma patients
2013
Targeting C4-Demethylating Genes in the Cholesterol Pathway Sensitizes Cancer Cells to EGF Receptor Inhibitors via Increased EGF Receptor Degradation
Sukhanova A, Gorin A, Serebriiskii IG, Gabitova L, Zheng H, Restifo D, Egleston BL, Cunningham D, Bagnyukova T, Liu H, Nikonova A, Adams GP, Zhou Y, Yang DH, Mehra R, Burtness B, Cai KQ, Klein-Szanto A, Kratz LE, Kelley RI, Weiner LM, Herman GE, Golemis EA, Astsaturov I. Targeting C4-Demethylating Genes in the Cholesterol Pathway Sensitizes Cancer Cells to EGF Receptor Inhibitors via Increased EGF Receptor Degradation. Cancer Discovery 2013, 3: 96-111. PMID: 23125191, PMCID: PMC3546138, DOI: 10.1158/2159-8290.cd-12-0031.Peer-Reviewed Original ResearchConceptsEGF receptorPathway genesDegradation of EGFROncogenic EGF receptorEGF receptor degradationBiosynthesis pathway genesPlatelet-derived growth factor receptorEndocytic traffickingVesicular traffickingEGF receptor inhibitorEGFR degradationDimerization partnerBioinformatics modelingGrowth factor receptorUnexpected roleReceptor degradationCancer cell viabilityNSDHLSC4MOLCholesterol pathwayGenesFactor receptorCancer resistanceEGFR antagonistsCancer cells
2010
A Phase I Study of the Pharmacokinetic and Safety Profiles of Oral Pazopanib With a High‐Fat or Low‐Fat Meal in Patients With Advanced Solid Tumors
Heath E, Chiorean E, Sweeney C, Hodge J, Lager J, Forman K, Malburg L, Arumugham T, Dar M, Suttle A, Gainer S, LoRusso P. A Phase I Study of the Pharmacokinetic and Safety Profiles of Oral Pazopanib With a High‐Fat or Low‐Fat Meal in Patients With Advanced Solid Tumors. Clinical Pharmacology & Therapeutics 2010, 88: 818-823. PMID: 20980999, DOI: 10.1038/clpt.2010.199.Peer-Reviewed Original ResearchConceptsHigh-fat mealAdvanced solid tumorsGrowth factor receptorSolid tumorsMaximum observed plasma concentrationPlasma concentration-time curvePhase IAdministration of pazopanibOral angiogenesis inhibitorVascular endothelial growth factor receptorFactor receptorEndothelial growth factor receptorLow-fat mealObserved plasma concentrationConcentration-time curvePlatelet-derived growth factor receptorDaily pazopanibOral pazopanibSafety profileSystemic exposureSingle doseSingle dosesPlasma concentrationsPazopanibFasted condition
2008
Dynamic change in phosphorylated platelet-derived growth factor receptor in peripheral blood leukocytes following docetaxel therapy predicts progression-free and overall survival in prostate cancer
Mathew P, Thall P, Wen S, Bucana C, Jones D, Horne E, Oh W, Morris M, Lee Y, Logothetis C, Lin S, Fidler I. Dynamic change in phosphorylated platelet-derived growth factor receptor in peripheral blood leukocytes following docetaxel therapy predicts progression-free and overall survival in prostate cancer. British Journal Of Cancer 2008, 99: 1426-1432. PMID: 18841158, PMCID: PMC2579696, DOI: 10.1038/sj.bjc.6604706.Peer-Reviewed Original ResearchConceptsPlatelet-derived growth factor receptorPlasma platelet-derived growth factorOverall survivalProgression-FreePlatelet-derived growth factor receptor phosphorylationGrowth factor receptorPeripheral blood leukocytesProstate cancerFactor receptorPlatelet-derived growth factor receptor inhibitionInferior median overall survivalMedian progression-free survivalPlacebo-controlled randomised studyBlood leukocytesMedian overall survivalProgression-free survivalMetastatic prostate cancerInhibitor imatinib mesylateIndividual treatment armsPlasma PDGF concentrationPlatelet-derived growth factorDocetaxel efficacyDocetaxel therapyImatinib armInferior survivalImatinib mesylate (Gleevec®) in advanced breast cancer-expressing C-Kit or PDGFR-β: clinical activity and biological correlations
Cristofanilli M, Morandi P, Krishnamurthy S, Reuben JM, Lee B, Francis D, Booser DJ, Green MC, Arun BK, Pusztai L, Lopez A, Islam R, Valero V, Hortobagyi GN. Imatinib mesylate (Gleevec®) in advanced breast cancer-expressing C-Kit or PDGFR-β: clinical activity and biological correlations. Annals Of Oncology 2008, 19: 1713-1719. PMID: 18515258, PMCID: PMC2735063, DOI: 10.1093/annonc/mdn352.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntineoplastic AgentsBenzamidesBreast NeoplasmsBreast Neoplasms, MaleCarcinoma, Ductal, BreastFemaleHumansImatinib MesylateImmunologic FactorsMaleMiddle AgedNeoplasm MetastasisPiperazinesProspective StudiesProtein Kinase InhibitorsProto-Oncogene Proteins c-kitPyrimidinesReceptor, Platelet-Derived Growth Factor betaConceptsMetastatic breast cancerPlatelet-derived growth factor receptorImatinib mesylateC-kitDisease progressionClinical activityB-fibroblast growth factorGrowth factorMedian overall survivalSerious adverse eventsPotential immunosuppressive effectsInterferon-gamma productionVascular endothelial growth factorAngiogenesis-related cytokinesEndothelial growth factorNovel molecular therapiesC-kit expressionGrowth factor receptorAdverse eventsObjective responseOverall survivalTreat analysisDismal prognosisMedian timeImmunomodulatory effects
2007
Platelet-Derived Growth Factor Receptor Inhibition and Chemotherapy for Castration-Resistant Prostate Cancer with Bone Metastases
Mathew P, Thall P, Bucana C, Oh W, Morris M, Jones D, Johnson M, Wen S, Pagliaro L, Tannir N, Tu S, Meluch A, Smith L, Cohen L, Kim S, Troncoso P, Fidler I, Logothetis C. Platelet-Derived Growth Factor Receptor Inhibition and Chemotherapy for Castration-Resistant Prostate Cancer with Bone Metastases. Clinical Cancer Research 2007, 13: 5816-5824. PMID: 17908974, DOI: 10.1158/1078-0432.ccr-07-1269.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBenzamidesBone NeoplasmsCastrationCohort StudiesDisease-Free SurvivalDocetaxelHumansImatinib MesylateMaleMiddle AgedNeoplasm MetastasisPiperazinesPlacebosProstatic NeoplasmsPyrimidinesReceptor, Platelet-Derived Growth Factor betaReceptors, Platelet-Derived Growth FactorTaxoidsConceptsPlatelet-derived growth factor receptorPlatelet-derived growth factor receptor inhibitionCastration-resistant prostate cancerBone metastasesProstate cancerPeripheral blood leukocytesP-PDGFRProgressive castration-resistant prostate cancerSerum bone-specific alkaline phosphataseMedian time to progressionProstate cancer bone metastasisBlood leukocytesBone-specific alkaline phosphataseGrade 3 toxicityUrine N-telopeptideProgression-free survivalTime to progressionBone turnover markersImatinib-treated patientsAdverse gastrointestinal eventsSecondary end pointsCancer bone metastasisEarly clinical evidenceGrowth factor receptorTaxane chemotherapySafety, Pharmacokinetics, and Efficacy of AMG 706, an Oral Multikinase Inhibitor, in Patients With Advanced Solid Tumors
Rosen LS, Kurzrock R, Mulay M, Van Vugt A, Purdom M, Ng C, Silverman J, Koutsoukos A, Sun YN, Bass MB, Xu RY, Polverino A, Wiezorek JS, Chang DD, Benjamin R, Herbst RS. Safety, Pharmacokinetics, and Efficacy of AMG 706, an Oral Multikinase Inhibitor, in Patients With Advanced Solid Tumors. Journal Of Clinical Oncology 2007, 25: 2369-2376. PMID: 17557949, DOI: 10.1200/jco.2006.07.8170.Peer-Reviewed Original ResearchConceptsMaximum-tolerated doseAMG 706Advanced solid tumorsSolid tumorsAdvanced refractory solid tumorsRefractory advanced solid tumorsVascular endothelial growth factor receptor 1Frequent adverse eventsRefractory solid tumorsDose-proportional mannerFactor receptorDose-finding studyOral multikinase inhibitorStudy of patientsPlacental growth factorGrowth factor receptor 1Platelet-derived growth factor receptorFactor receptor 1Stem cell factor receptorGrowth factor receptorStable diseaseKinase domain receptorAdverse eventsPartial responseProgressive disease
2006
79 POSTER Correlative results of in-vivo monitoring of platelet-derived growth factor receptor (PDGFR) activation status in a randomized placebocontrolled trial of docetaxel +/− imatinib in castration-resistant prostate cancer (CRPC) and bone metastases (BM)
Mathew P, Thall P, Wen S, Horne E, Johnson M, Oh W, Morris M, Logothetis C, Fidler I, Bucana C. 79 POSTER Correlative results of in-vivo monitoring of platelet-derived growth factor receptor (PDGFR) activation status in a randomized placebocontrolled trial of docetaxel +/− imatinib in castration-resistant prostate cancer (CRPC) and bone metastases (BM). European Journal Of Cancer Supplements 2006, 4: 28. DOI: 10.1016/s1359-6349(06)70085-4.Peer-Reviewed Original ResearchPreliminary results of a randomized placebo-controlled double-blind trial of weekly docetaxel combined with imatinib in men with metastatic androgen-independent prostate cancer (AIPC) and bone metastases (BM)
Mathew P, Thall P, Johnson M, Oh W, Meluch A, Morris M, Troncoso P, Bucana C, Fidler I, Logothetis C. Preliminary results of a randomized placebo-controlled double-blind trial of weekly docetaxel combined with imatinib in men with metastatic androgen-independent prostate cancer (AIPC) and bone metastases (BM). Journal Of Clinical Oncology 2006, 24: 4562-4562. DOI: 10.1200/jco.2006.24.18_suppl.4562.Peer-Reviewed Original ResearchAndrogen-independent prostate cancerTime to progressionBone metastasesPlatelet-derived growth factor receptorPartial responseProgressive androgen-independent prostate cancerMetastatic androgen-independent prostate cancerHigh-dose steroid useMedian time to progressionRandomized placebo-controlled double-blind trialGrade 3 AEsMedian overall survivalBone marrow biopsyECOG performance scoreGastrointestinal adverse eventsPerforated sigmoid diverticulitisGrowth factor receptorPerformance scoresWeekly docetaxelProgression-FreeStable diseaseMarrow biopsyTumor responseSigmoid diverticulitisDocetaxel activity
2005
Pharmacodynamic Analysis of Target Inhibition and Endothelial Cell Death in Tumors Treated with the Vascular Endothelial Growth Factor Receptor Antagonists SU5416 or SU6668
Davis DW, Takamori R, Raut CP, Xiong HQ, Herbst RS, Stadler WM, Heymach JV, Demetri GD, Rashid A, Shen Y, Wen S, Abbruzzese JL, McConkey DJ. Pharmacodynamic Analysis of Target Inhibition and Endothelial Cell Death in Tumors Treated with the Vascular Endothelial Growth Factor Receptor Antagonists SU5416 or SU6668. Clinical Cancer Research 2005, 11: 678-689. PMID: 15701856, DOI: 10.1158/1078-0432.678.11.2.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAnimalsApoptosisDose-Response Relationship, DrugEndothelium, VascularFemaleHumansIndolesMaleMiceMice, NudeMiddle AgedNeovascularization, PathologicOxindolesPancreatic NeoplasmsPhosphorylationPropionatesPyrrolesReceptor, Platelet-Derived Growth Factor betaTransplantation, HeterologousVascular Endothelial Growth Factor Receptor-2ConceptsPlatelet-derived growth factor receptorTumor microvessel densityGrowth factor receptorMicrovessel densityCell apoptosisVascular endothelial growth factor receptorAdvanced solid malignanciesFactor receptorEndothelial growth factor receptorPrimary patient tumorsG core biopsyDose-dependent effectPhosphorylated VEGFR-2Primary human tumorsEndothelial cell deathCell deathEndothelial cell apoptosisTumor cell apoptosisTumor cell deathPost therapyCore biopsyPharmacodynamic analysisSolid malignanciesVessel sizeClinical trials
2004
Bidirectional Signaling Links the Abelson Kinases to the Platelet-Derived Growth Factor Receptor
Plattner R, Koleske AJ, Kazlauskas A, Pendergast AM. Bidirectional Signaling Links the Abelson Kinases to the Platelet-Derived Growth Factor Receptor. Molecular And Cellular Biology 2004, 24: 2573-2583. PMID: 14993293, PMCID: PMC355852, DOI: 10.1128/mcb.24.6.2573-2583.2004.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsCell LineChemotaxisEnzyme ActivationIn Vitro TechniquesMacromolecular SubstancesMiceNIH 3T3 CellsPhospholipase C gammaPhosphorylationProtein-Tyrosine KinasesProto-Oncogene Proteins c-ablReceptor, Platelet-Derived Growth Factor alphaReceptor, Platelet-Derived Growth Factor betaRecombinant ProteinsSignal TransductionType C PhospholipasesConceptsPDGF beta receptorPlatelet-derived growth factorC-AblPLC-gamma1C-Abl nonreceptor tyrosine kinaseTyrosine kinaseGrowth factor signalsSrc family kinasesC-Abl functionNonreceptor tyrosine kinaseTyrosine kinase activityPlatelet-derived growth factor receptorAbundant phosphoinositideMembrane rufflingInducible complexNonredundant functionsFamily kinasesMembrane proteinsC-gamma1Factor signalsGrowth factor receptorAbelson kinaseKinase activityBiological processesChemotaxis defectEffects of Cyclic Strain on Vascular Cells
Kakisis JD, Liapis CD, Sumpio BE. Effects of Cyclic Strain on Vascular Cells. Endothelium 2004, 11: 17-28. PMID: 15203876, DOI: 10.1080/10623320490432452.Peer-Reviewed Original ResearchConceptsCAMP-responsive elementVascular cell morphologyExtracellular mechanical signalsMitogen-activated protein kinaseProtein kinase CPlatelet-derived growth factor receptorEarly growth responseCells senseNumerous genesActivator proteinTranscription factorsProtein kinaseGrowth factor receptorAP-2Chemical signalsSecond messengerKinase CG proteinsMechanical signalsCell nucleiGrowth responseIon channelsCell morphologyFactor receptorCell proliferation
2003
Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies.
London CA, Hannah AL, Zadovoskaya R, Chien MB, Kollias-Baker C, Rosenberg M, Downing S, Post G, Boucher J, Shenoy N, Mendel DB, McMahon G, Cherrington JM. Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies. Clinical Cancer Research 2003, 9: 2755-68. PMID: 12855656.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic AgentsDog DiseasesDogsDose-Response Relationship, DrugEnzyme InhibitorsFemaleIndolesInhibitory Concentration 50MaleModels, ChemicalMutationNeoplasmsProto-Oncogene Proteins c-kitPyrrolesReceptor Protein-Tyrosine KinasesReceptors, Vascular Endothelial Growth FactorTime FactorsTomography, X-Ray ComputedConceptsReceptor tyrosine kinase inhibitorsTyrosine kinase inhibitorsGrowth factor receptorKinase inhibitorsSpontaneous malignanciesSpontaneous tumorsSmall molecule receptor tyrosine kinase inhibitorPhase I dose-escalating studyDose-escalating studyMeasurable objective responseSimilarities of canineVascular endothelial growth factor receptorStandard treatment regimensFactor receptorPhase I trialEndothelial growth factor receptorOverall response rateSoft tissue sarcomasPlatelet-derived growth factor receptorMast cell tumorsVariety of cancersStable diseaseObjective responseOral therapyProgressive disease
2001
Sonic hedgehog-dependent emergence of oligodendrocytes in the telencephalon: evidence for a source of oligodendrocytes in the olfactory bulb that is independent of PDGFRalpha signaling.
Spassky N, Heydon K, Mangatal A, Jankovski A, Olivier C, Queraud-Lesaux F, Goujet-Zalc C, Thomas J, Zalc B. Sonic hedgehog-dependent emergence of oligodendrocytes in the telencephalon: evidence for a source of oligodendrocytes in the olfactory bulb that is independent of PDGFRalpha signaling. Development 2001, 128: 4993-5004. PMID: 11748136, DOI: 10.1242/dev.128.24.4993.Peer-Reviewed Original ResearchConceptsSpinal cordPlatelet-derived growth factor receptorOlfactory bulbOligodendrocyte progenitorsInduction of oligodendrocytesSource of oligodendrocytesAnterior entopeduncular areaMedial ganglionic eminenceExpression of PLPGrowth factor receptorRostral palliumTelencephalic oligodendrocytesGanglionic eminenceVentricular focusOligodendroglial lineageCordRostral telencephalonOligodendrocytesOligodendrocyte lineageFactor receptorVentricular progenitorsTelencephalonMouse telencephalonSonic hedgehogMolecular mechanisms
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply